Test Price
2,800 AEDโ Home Collection Available
P3H1 Gene (Osteogenesis Imperfecta Type VIII) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Trust Signals & Service Guarantees
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM โ 11 PM).
- Clinical Guidance: Telephonic Post-Test Genetic Counselling included in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Clinical Credentials
This targeted NGS analysis of the P3H1 gene delivers definitive molecular diagnosis for autosomal recessive Osteogenesis Imperfecta Type VIII. All testing is performed at our DHA-licensed laboratory facility in Dubai Healthcare City under ISO 9001:2015 quality management standards. Results are correlated with clinical findings by a Consultant Medical Geneticist.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) based genetic test sequences the complete coding region and splice-site boundaries of the P3H1 gene to detect pathogenic mutations responsible for Osteogenesis Imperfecta Type VIII, a severe autosomal recessive collagen disorder characterised by recurrent fractures, bone deformity, and blue sclera. Early molecular diagnosis enables families to plan proactive management, reduce fracture incidence, and make informed reproductive decisions. The test requires a standard peripheral whole blood sample (5 mL EDTA tube) with a turnaround time of 3โ4 weeks.
| Feature | P3H1 Targeted NGS Test | Whole Exome Sequencing (WES) |
|---|---|---|
| Precision | Targeted deep sequencing of P3H1 gene with >99% sensitivity for coding and splice-site variants | Broad analysis of all exons; may miss deep intronic or low-coverage regions |
| Methodology | NGS enrichment + confirmatory Sanger sequencing for all reported variants | NGS with bioinformatic filtering; secondary confirmation often required |
| Turnaround Time | 3โ4 Weeks | 6โ8 Weeks |
| Cost Efficiency | Focused on clinically actionable gene with lower overall cost | Higher cost; incidental findings require additional counselling |
Physician Insight & Safety Protocols
โAs a DHA-licensed Consultant Medical Geneticist, I stress that a genetic test result alone does not define a patientโs clinical trajectory. Accurate interpretation requires correlation with physical examination findings, detailed family history, and a multidisciplinary care approach. I strongly encourage all patients to review their results with their referring physician and a certified genetic counsellor before making any medical or lifestyle changes.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication & Clinical Management
Do not discontinue or adjust any prescribed medication, including bisphosphonate therapy or orthopaedic interventions, without prior consultation with your treating physician. This genetic test is a diagnostic adjunct and does not replace ongoing clinical monitoring or established fracture management protocols for Osteogenesis Imperfecta.
Exclusion Criteria & Emergency Red Flags
- Not suitable for individuals who have received an allogeneic blood transfusion within the past 2 weeks; defer testing to avoid false results from donor DNA contamination.
- Not appropriate for individuals with active haematologic malignancy that may compromise DNA extraction quality.
- Minors require explicit written parental or guardian consent in accordance with UAE Federal Law No. 2 of 2019 concerning health information use.
- If you experience sudden severe bone pain, respiratory distress, or acute onset of fractures, seek immediate emergency medical attention. These symptoms may reflect acute disease progression unrelated to the testing procedure.
Patient FAQ & Clinical Guidance
1. What clinical conditions does the P3H1 gene test identify?
This test detects pathogenic variants in the P3H1 gene that cause autosomal recessive Osteogenesis Imperfecta Type VIII, a severe collagen disorder characterised by frequent fractures, long-bone deformities, blue or grey sclera, and dentinogenesis imperfecta. Early molecular confirmation guides orthopaedic surveillance, physical therapy, and pharmacological intervention to reduce fracture burden.
2. Why is Next-Generation Sequencing (NGS) the recommended methodology for P3H1 analysis?
NGS provides comprehensive coverage of the entire P3H1 coding region, all exon-intron boundaries, and untranslated regions, enabling detection of point mutations, small insertions and deletions, and copy number variants with greater than 99% sensitivity and specificity. Confirmatory Sanger sequencing ensures every clinically reported variant is independently verified, eliminating false positives.
3. Who should consider undergoing the P3H1 genetic test?
This test is indicated for individuals with clinical suspicion of Osteogenesis Imperfecta Type VIII, including those with unexplained recurrent fractures, bone deformity, short stature, and family history of OI. It is also recommended for carrier testing in consanguineous couples or those with a known family history of P3H1 mutations, enabling informed reproductive planning.
4. How soon will I receive my results and what post-test support is available?
Results are available within 3โ4 weeks from sample receipt. A dedicated telephonic post-test clinical guidance session with a certified genetic counsellor is included to interpret your results, discuss recurrence risks, and coordinate follow-up care with your referring physician or a specialist in skeletal dysplasia.
UAE Regulatory & Data Privacy Adherence
Clinical & Logistical Metadata
| Test Name | P3H1 Gene (Osteogenesis Imperfecta Type VIII) Genetic Test โ Targeted NGS Analysis |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (5 mL EDTA tube) โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available (daily 8 AM โ 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) with confirmatory Sanger sequencing for all clinically reported variants |
| ICD-10-CM Code | Q78.0 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians